Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02475161 · ClinicalTrials.gov registry record · Phase 1
A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT02475161 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 16 participants.
The verdict
NCT02475161, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the effects of daily administration of rabeprazole on the single-dose pharmacokinetics of JNJ-42847922 in healthy participants.
Interventions
- DRUG Rabeprazole
- DRUG JNJ-42847922
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02475161
The ClinicalTrials.gov registry entry for NCT02475161 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rabeprazole is the first listed.
NCT02475161 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02475161 about?
NCT02475161 is a clinical study titled "A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants". The purpose of this study is to assess the effects of daily administration of rabeprazole on the single-dose pharmacokinetics of JNJ-42847922 in healthy participants.
What is the current status of trial NCT02475161?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2015-06. Estimated completion is 2015-07.
What interventions are being tested in trial NCT02475161?
The interventions under investigation include: Rabeprazole (DRUG), JNJ-42847922 (DRUG).
Who is sponsoring clinical trial NCT02475161?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.